This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

Tipranks - Tipranks - Thu Aug 6, 9:42AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM).

Claim 55% Off TipRanks

Gilead Sciences (GILD)

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Gilead Sciences. The company’s shares closed last Wednesday at $132.11.

According to TipRanks.com, Raffat is a 4-star analyst with an average return of 9.4% and a 51.0% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Kailera Therapeutics, Inc., Parabilis Medicines, Inc., and Elanco Animal Health. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $159.00, a 16.9% upside from current levels. In a report issued on July 22, Bernstein also maintained a Buy rating on the stock with a $160.00 price target.

See today’s best-performing stocks on TipRanks >>

Ultragenyx Pharmaceutical (RARE)

Wedbush analyst Laura Chico maintained a Hold rating on Ultragenyx Pharmaceutical today and set a price target of $30.00. The company’s shares closed last Wednesday at $25.00.

According to TipRanks.com, Chico is a 5-star analyst with an average return of 15.0% and a 54.1% success rate. Chico covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Maze Therapeutics, Inc., and Alto Neuroscience, Inc. ;'>

Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $52.07, representing an 82.8% upside. In a report issued on July 25, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $29.00 price target.

Beam Therapeutics (BEAM)

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Beam Therapeutics, with a price target of $65.00. The company’s shares closed last Wednesday at $27.54.

According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 22.6% and a 54.7% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Odyssey Therapeutics, Inc., and Perspective Therapeutics. ;'>

Currently, the analyst consensus on Beam Therapeutics is a Strong Buy with an average price target of $53.27, implying an 87.4% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).